- Conditions
- Homocystinuria Due to CBS Deficiency
- Interventions
- Not listed
- Lead sponsor
- Travere Therapeutics, Inc.
- Industry
- Eligibility
- 1 Year to 65 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 18,626
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pain
- Interventions
- VX-993
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Lymphoma
- Interventions
- rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, tositumomab and iodine I 131 tositumomab
- Biological · Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 78
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Duarte, California + 46 more
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High Dose, Placebo
- Biological · Other
- Lead sponsor
- Uniquity One (UNI)
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 38
- States / cities
- Dothan, Alabama • Glendale, Arizona • Peoria, Arizona + 35 more
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases
- Interventions
- MINT-TLC, Control Condition
- Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Meningococcal Immunisation (Healthy Volunteers)
- Interventions
- Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine, Meningococcal Group B vaccine (Trumenba®), Meningococcal group B vaccine (Bexsero®)
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 13 Years to 26 Years
- Enrollment
- 570 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • San Diego, California • Bardstown, Kentucky + 20 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- resveratrol
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Central Nervous System Malignancies, Ependymoma
- Interventions
- 5-fluorouracil
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 1 Month to 21 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Malignant Neoplasms Brain
- Interventions
- RNA-loaded dendritic cell vaccine, basiliximab
- Biological · Drug
- Lead sponsor
- Gary Archer Ph.D.
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
- Interventions
- 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan
- Drug
- Lead sponsor
- Actuate Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Orange, California + 34 more
- Conditions
- Autism Spectrum Disorder
- Interventions
- ML-004 (IR)/(ER) tablet
- Drug
- Lead sponsor
- MapLight Therapeutics
- Industry
- Eligibility
- 12 Years to 46 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 18
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Glendale, California + 15 more
- Conditions
- Healthy, Language
- Interventions
- Incidental training, Explicit training, Classroom training, Classroom and incidental training, Classroom and explicit training
- Behavioral
- Lead sponsor
- Carnegie Mellon University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Simtuzumab, Simtuzumab placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more
- Conditions
- Aging
- Interventions
- Jintronix
- Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Screen Time Exposure
- Interventions
- Human-developed negative body image warning, Voluntary warning, Human-developed depression and anxiety warning, Human-developed addiction warning, Human-developed sleep warning, Human-developed mental health harms to young people warning, Human-developed warning that social media has not been proven safe, Control message, California's proposed social media warning, Artificial-intelligence-developed depression and anxiety warning, Artificial-intelligence-developed negative body image warning, Artificial-intelligence-developed addiction warning, Artificial-intelligence-developed sleep warning, Artificial-intelligence-developed mental health harms to young people warning, Artificial-intelligence-developed warning that social media has not been proven safe
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 13 Years to 29 Years
- Enrollment
- 1,012 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Muscle Hypertrophy, Muscle Strength
- Interventions
- Resistance training
- Behavioral
- Lead sponsor
- Auburn University
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Auburn, Alabama
- Conditions
- Syncope
- Interventions
- Emergency Department Observation Protocol, Unstructured, inpatient evaluation
- Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Boston, Massachusetts • Royal Oaks, Michigan + 1 more
- Conditions
- Stage IV Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
- Interventions
- docetaxel, thalidomide
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older · Male only
- Timeline
- 1999 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Nurse's Role
- Interventions
- Not listed
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Chronic Pain, Mild Cognitive Impairment, Older Adults, Physical Activity
- Interventions
- Active Brains 1, Active Brains 2
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Erwinase
- Drug
- Lead sponsor
- Ashkan Emadi
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diabetes, Type 1 Diabetes
- Interventions
- Unified protocol for cognitive behavioral therapy (UP-CBT), Continuous Glucose Monitoring (CGM)
- Behavioral · Device
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • The Bronx, New York
- Conditions
- Aging, Healthy
- Interventions
- Elamipretide will be supplied as a sterile 5.0 mL single-patient, multi-dose glass vial containing 3.75 mL of elamipretide solution (elamipretide [80 mg/mL], phosphate buffer, and benzyl alcohol)
- Drug
- Lead sponsor
- David Marcinek
- Other
- Eligibility
- 65 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Opioid-use Disorder, Heroin Abuse, Craving, Transcranial Magnetic Stimulation
- Interventions
- Repetitive Transcranial Magnetic Stimulation, Sham Repetitive Transcranial Magnetic Stimulation
- Device
- Lead sponsor
- University of Nevada, Las Vegas
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada